Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer (Abstract GS4-07).
Matteo Lambertini, MD, of the Institut Jules Bordet, discusses the results of five clinical trials investigating temporary ovarian suppression with gonadotropin-releasing hormone a...
Vered Stearns, MD, of Johns Hopkins University, and Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discuss two key topics in adjuvant treatment: en...
Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients ...
Rowan T. Chlebowski, MD, PhD, of the City of Hope National Medical Center, discusses 11-year followup results that showed a significantly lower breast cancer incidence among women ...
Silvia C. Formenti, MD, of Weill Cornell Medicine, discusses the high therapeutic potential of combining radiotherapy with immunotherapy and findings that show radiation dose and f...